OCUL - OCULAR THERAPEUTIX, INC
IEX Last Trade
8.59
0.040 0.466%
Share volume: 11,956
Last Updated: Thu 26 Dec 2024 08:30:06 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
1.30%
PREVIOUS CLOSE
CHG
CHG%
$8.55
0.04
0.47%
Fundamental analysis
28%
Profitability
25%
Dept financing
43%
Liquidity
75%
Performance
15%
Performance
5 Days
-2.69%
1 Month
-14.56%
3 Months
-5.13%
6 Months
25.64%
1 Year
89.75%
2 Year
211.99%
Key data
Stock price
$8.59
DAY RANGE
$8.31 - $8.59
52 WEEK RANGE
$4.00 - $11.78
52 WEEK CHANGE
$84.29
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
Company detail
CEO: Antony Mattessich
Region: US
Website: ocutx.com
Employees: 230
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: ocutx.com
Employees: 230
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Ocular Therapeutix, Inc. focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases.
Recent news